Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

Presentation on Wednesday, January 11, 2017, at 5:00 p.m. Pacific Time

BRISBANE, Calif.--()--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2017, at 5:00 p.m. Pacific Time.

A live audio webcast of the presentation and breakout session will be accessible from the Investor Relations section of the Aimmune website at www.aimmune.com. A replay of the webcast will be available at www.aimmune.com for up to 90 days following the event.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts. For more information, please see www.aimmune.com.

Contacts

Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com

Recent Stories

RSS feed for Aimmune Therapeutics, Inc.

Release Summary

Aimmune Therapeutics to present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, at 5 p.m. Pacific Time.

Aimmune Therapeutics, Inc.